Global Alzheimer’s Disease Therapeutics & Diagnostics Market Forecast 2022-2030

Global Alzheimer’s Disease Therapeutics & Diagnostics Market Forecast 2022-2030

KEY FINDINGS

The global Alzheimer’s disease therapeutics & diagnostics market is anticipated to grow at a 6.61% CAGR during the estimation period between 2022 to 2030. The market growth is accelerated by the rise in the pervasiveness of Alzheimer’s disease, emerging novel diagnostic technologies, and the increasing number of pipeline drugs.

MARKET INSIGHTS

Alzheimer’s is a neurodegenerative disease characterized by chronic inflammation and accumulation of beta-amyloid peptides. The elderly usually suffer from Alzheimer’s disease, which gradually damages their thinking skills and memory, eventually destroying their ability to perform the simplest daily tasks. Alzheimer’s disease is the major reason for dementia among the older population. Therefore, the rising geriatric population is a key driver for the global Alzheimer’s disease therapeutics and diagnostics market.

Several novel diagnostics technologies have been discovered for Alzheimer’s disease (AD), including the invention that identifies mutated proteins in subcellular compartments. This invention describes these mutations that lead to the redistribution of crucial cellular organelles.

Furthermore, alteration of organelles distribution can be a powerful diagnostic tool, an assay to screen novel therapeutic compounds for Alzheimer’s disease. This technology’s advantage includes identifying mutated proteins, which are directly involved in the genesis of AD. Thus, there is potential for providing a superior AD diagnosis compared to current diagnostic tests.

REGIONAL INSIGHTS

The global Alzheimer’s disease therapeutics & diagnostics market assessment entails the analysis of Europe, Asia-Pacific, North America, and Rest of World. The Asia-Pacific region is anticipated to propel with the highest CAGR by 2030, owing to the rapidly increasing geriatric population and government initiative to develop medicines to cure AD.

COMPETITIVE INSIGHTS

The competition in the global market is significantly high owing to the presence of generic medicines. Furthermore, strong competition exists among the key players in developing new diagnostics methodologies and treatments. However, the industry is observing meaningful strategic partnerships to enhance market presence.

Some important global players include Merck & Co Inc, Cognoptix Inc, Eli Lilly & Company, Johnson & Johnson, etc.

Our report offerings include:
• Explore key findings of the overall market
• Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
• Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
• Market Segmentation caters to a thorough assessment of key segments with their market estimations
• Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
• Key analytics: Porter’s Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
• Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
• Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments


1. Research Scope & Methodology
1.1. Study Objectives
1.2. Scope Of Study
1.3. Methodology
1.4. Assumptions & Limitations
2. Executive Summary
2.1. Market Size & Estimates
2.2. Market Overview
3. Market Dynamics
3.1. Parent Market Analysis
3.2. Key Drivers
3.2.1. Growing Geriatric Population
3.2.2. Rising Pervasiveness Of Alzheimer’s Disease
3.2.3. Emerging Novel Diagnostic Technologies
3.2.4. Increasing Pipeline Drugs
3.3. Key Restraints
3.3.1. Failure Of The Late-stage Drugs
3.3.2. Stringent Government Regulations
3.3.3. Lack Of The Availability Of Surrogate Markers
4. Key Analytics
4.1. Timeline Of Alzheimer’s Disease Therapeutics & Diagnostics Market
4.2. Phases And Sternness Of Alzheimer’s Disease
4.3. Impact Of Covid-19 On Alzheimer’s Disease Therapeutics & Diagnostics Market
4.4. Key Market Trends
4.5. Porter’s Five Forces Analysis
4.5.1. Buyers Power
4.5.2. Suppliers Power
4.5.3. Substitution
4.5.4. New Entrants
4.5.5. Industry Rivalry
4.6. Key Buying Criteria
4.7. Supply Chain Analysis
4.8. Opportunity Matrix
4.9. Vendor Landscape
5. Market By Therapeutics & Diagnostics
5.1. Therapeutics
5.1.1. Drugs
5.1.1.1. Marketed Drugs
5.1.1.2. Pipeline Drugs
5.1.2. Disease Stage
5.1.2.1. Late-stage: Severe Ad
5.1.2.2. Early/Middle Stage: Mild To Moderate Ad
5.1.2.3. Prodromal Stage
5.1.3. Generic & Branded
5.1.3.1. Branded
5.1.3.2. Generic
5.2. Diagnostics
5.2.1. Lumbar Puncture Test
5.2.2. Positron Emission Tomography
5.2.3. Electroencephalography
5.2.4. Magnetic Resonance Imaging
5.2.5. Computed Tomography
5.2.6. Blood Test
5.2.7. Other Diagnostics
6. Geographical Analysis
6.1. North America
6.1.1. Market Size & Estimates
6.1.2. Key Growth Enablers
6.1.3. Key Challenges
6.1.4. Key Players
6.1.5. Country Analysis
6.1.5.1. United States
6.1.5.2. Canada
6.2. Europe
6.2.1. Market Size & Estimates
6.2.2. Key Growth Enablers
6.2.3. Key Challenges
6.2.4. Key Players
6.2.5. Country Analysis
6.2.5.1. United Kingdom
6.2.5.2. Germany
6.2.5.3. France
6.2.5.4. Italy
6.2.5.5. Belgium
6.2.5.6. Poland
6.2.5.7. Rest Of Europe
6.3. Asia-pacific
6.3.1. Market Size & Estimates
6.3.2. Key Growth Enablers
6.3.3. Key Challenges
6.3.4. Key Players
6.3.5. Country Analysis
6.3.5.1. China
6.3.5.2. Japan
6.3.5.3. India
6.3.5.4. South Korea
6.3.5.5. Indonesia
6.3.5.6. Thailand
6.3.5.7. Vietnam
6.3.5.8. Australia & New Zealand
6.3.5.9. Rest Of Asia-pacific
6.4. Rest Of World
6.4.1. Market Size & Estimates
6.4.2. Key Growth Enablers
6.4.3. Key Challenges
6.4.4. Key Players
6.4.5. Regional Analysis
6.4.5.1. Latin America
6.4.5.2. Middle East & Africa
7. Competitive Landscape
7.1. Key Strategic Developments
7.1.1. Mergers & Acquisitions
7.1.2. Product Launches & Developments
7.1.3. Partnerships & Agreements
7.1.4. Business Expansions, Announcements, & Divestitures
7.2. Company Profiles
7.2.1. Allergan Plc (Acquired By Abbvie)
7.2.2. Amarantus Bioscience Holdings Inc
7.2.3. Baxter International Inc
7.2.4. Biogen Inc
7.2.5. Cognoptix Inc
7.2.6. Eisai Co Ltd
7.2.7. Eli Lilly & Company
7.2.8. F Hoffmann-la Roche
7.2.9. Ge Healthcare
7.2.10. Johnson & Johnson
7.2.11. Lupin Limited
7.2.12. Merck & Co Inc
7.2.13. Novartis Ag
7.2.14. Pfizer Inc
7.2.15. Siemens Healthineers Ag
7.2.16. Sun Pharmaceuticals Industries Ltd
7.2.17. Teva Pharmaceutical Industries Limited
7.2.18. Zydus Cadila

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook